A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)
Purpose
The main goal of this trial is to evaluate the efficacy and safety of Lu AF82422 for the treatment of participants with Multiple System Atrophy (MSA).
Condition
- Multiple System Atrophy
Eligibility
- Eligible Ages
- Between 40 Years and 75 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- The participant has a diagnosis of clinically established multiple system atrophy parkinsonian type (MSA-P) or multiple system atrophy cerebellar type (MSA-C), or clinically probable MSA-P or MSA-C, according to the 2022 Movement Disorders Society (MDS) criteria for the diagnosis of MSA at the Screening Visit. - The participant had onset of motor MSA symptoms (i.e., parkinsonian and/or cerebellar) within 5 years prior to the Screening Visit in the judgement of the investigator. - The participant has an anticipated survival of >3 years, in the opinion of the investigator, at the Screening Visit. - The participant has suitable peripheral venous access for investigational medicinal product (IMP) administration and blood sampling. - The participant has an UMSARS Part I score ≤16 (omitting item 11 on sexual function) at the Screening Visit.
Exclusion Criteria
- The participant has previously been dosed with Lu AF82422. - The participant has taken any IMP <3 months or <5 half lives of that product, whichever is longer, prior to the first dose of IMP. - The participant has 2 or more first degree relatives with a history of MSA. - The participant, if of MSA-P subtype, has unexplained anosmia (not explained by other common causes such as allergic rhinitis or smoking, nasal structural lesions, or nasal surgery) on olfactory testing at the Screening Visit. - The participant has evidence (clinically or on magnetic resonance imaging (MRI)) and/or history of any clinically significant disease or condition other than MSA, that is, in the investigator's opinion, likely to affect CNS functioning, e.g., serious neurological disorder, other intracranial or systemic disease. - The participant has a current diagnosis of movement disorders that could mimic MSA, e.g., Parkinson' disease, dementia with Lewy bodies, essential tremor, progressive supranuclear palsy, spinocerebellar ataxia, spastic paraparesis, corticobasal degeneration, or vascular, pharmacological, or post-encephalitic parkinsonism, per investigator discretion. Participants who have previously been incorrectly diagnosed with Parkinson's disease will not be excluded. Other protocol-defined inclusion and exclusion criteria apply.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Lu AF82422 Low Dose |
Participants will receive Lu AF82422 by intravenous infusion |
|
|
Experimental Lu AF82422 High Dose |
Participants will receive Lu AF82422 by intravenous infusion |
|
|
Placebo Comparator Placebo |
Participants will receive commercially available saline solution for infusion |
|
Recruiting Locations
CenExel Rocky Mountain Clinical Research, LLC
Englewood, Colorado 80113
Englewood, Colorado 80113
Parkinson's Disease And Movement Disorder Center Of Boca Raton
Boca Raton, Florida 33486
Boca Raton, Florida 33486
University of Florida Norman Fixel Institute for Neurological Diseases
Gainesville, Florida 32608
Gainesville, Florida 32608
QUEST Research Institute
Farmington Hills, Michigan 48334
Farmington Hills, Michigan 48334
University Nebraska Medical Center
Omaha, Nebraska 68198-8440
Omaha, Nebraska 68198-8440
Columbia University Medical Center - The Neurological Institute of New York
New York, New York 10032-3726
New York, New York 10032-3726
Baylor College Of Medicine
Houston, Texas 77030
Houston, Texas 77030
Inland Northwest Research
Spokane, Washington 99202
Spokane, Washington 99202
More Details
- NCT ID
- NCT06706622
- Status
- Recruiting
- Sponsor
- H. Lundbeck A/S
Detailed Description
This study will consist of a 3-6-week screening period, a 72-week placebo-controlled period (PCP), and will include a 72-week optional dose-blinded open-label treatment extension (OLE) period. Participants in the PCP will be randomized to Lu AF82422 high dose, Lu AF82422 low dose or placebo (1:1:1). All participants entering the OLE will receive Lu AF82422 during the OLE. Participants will receive intravenous infusions approximately every 4 weeks during both the PCP and OLE.